非小细胞肺癌VATS肺叶切除加系统纵隔淋巴结清扫后不同胸膜腔灌洗液量的临床获益比较:随机对照试验研究方案
本研究为随机对照试验方案,拟纳入400例接受VATS肺叶切除加系统纵隔淋巴结清扫的非小细胞肺癌患者,随机分为500 mL与3000 mL胸膜腔灌洗液两组。主要结局为术后第1天白细胞、中性粒细胞及炎症因子水平,次要结局包括术后第2、3天上述指标、发热发生率、胸腔引流量与引流时间、住院时间及术后30天内并发症和需穿刺引流的胸腔积液发生率。该试验旨在确定胸壁关闭前合适的胸膜腔灌洗液量。
要点
- 拟纳入400例NSCLC患者随机比较500 mL与3000 mL胸膜腔灌洗液。
- 主要结局为术后第1天白细胞、中性粒细胞及炎症因子水平。
- 次要结局涵盖术后发热、胸腔引流、住院时间及30天内并发症。
核心结论
- 该随机对照试验将首次比较VATS肺叶切除加系统纵隔淋巴结清扫后不同胸膜腔灌洗液量的临床结局,以确定胸壁关闭前合适的灌洗液量。
研究设计与样本
- 研究方案为随机对照试验,拟纳入400例接受VATS肺叶切除加系统纵隔淋巴结清扫的非小细胞肺癌患者。
- 患者随机分为A组(500 mL胸膜腔灌洗液)和B组(3000 mL胸膜腔灌洗液)。
- 分析内容包括有效性分析和安全性分析,并将进行亚组分析以识别潜在影响因素。
- 试验已于2019年3月17日在中国临床试验注册中心注册,注册号ChiCTR 1900021950。
关键数值与推荐
- 主要结局为术后第1天白细胞、中性粒细胞及炎症因子水平。
- 次要结局包括术后第2天和第3天白细胞、中性粒细胞及炎症因子水平。
- 次要结局包括术后第1、2、3天发热发生率。
- 次要结局包括术后前3天胸腔引流量、引流持续时间及术后住院时间。
- 次要结局包括术后30天内并发症(切口感染、疼痛、肺不张、出血等)发生率及需胸腔穿刺或引流的胸腔积液发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pleural lavage is regularly performed before closing the chest wall in pulmonary surgeries to prevent pleural implantation of tumor cells and postoperative infection. However, scant data could be found in the literature regarding the optimal regimen for performing pleural lavage. To establish a proper volume of pleural lavage, we herein designed a protocol for a randomized controlled trial. METHODS: A total of 400 participants with non-small cell lung cancer undergoing video-assisted thoracoscopic surgery (VATS) lobectomy and systematic mediastinal lymph node dissection (MLND) will be randomly assigned to one of two groups: group A (500 mL pleural lavage fluid) and group B (3000 mL pleural lavage fluid). The primary outcomes include the levels of leukocytes, neutrophils, and inflammatory factors on the first postoperative day. The secondary outcomes include (i) the levels of leukocytes, neutrophils, and inflammatory factors on the second and third postoperative days; (ii) the incidence of postoperative fever on the first, second, and third postoperative days; (iii) the volumes of chest drainage within the first 3 operative days, the duration of drainage, and postoperative hospitalization; and (iv) the incidence of postoperative complications (incision infection, pain, atelectasis, hemorrhage, etc.) and the incidence of pleural effusion requiring thoracic puncture or drainage within 30 days after surgery. The main content of the analysis includes effectiveness and safety analysis. We will perform subgroup analyses to identify potential influence factors. DISCUSSION: As far as we know, this will be the first randomized controlled trial to compare the clinical outcomes between different volumes of pleural lavage fluid following VATS and MLND. Findings from this trial will determine the appropriate amount of pleural lavage before chest wall closure. TRIAL REGISTRATION: This study was registered with the Chinese Clinical Trial Registry ( on 17 March 2019. ChiCTR 1900021950).
引用
- Zhou J, Liu C, Man S, et al. Comparison of the clinical benefits for non-small cell lung cancer patients between different volume of pleural lavage fluid following video-assisted thoracoscopic lobectomy and systematic mediastinal lymph node dissection: study protocol for a randomized controlled trial. Trials. 2020. PMID: 32106877. doi:10.1186/s13063-020-4146-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。